Biotech Archives - Page 84 of 795

2 minute read

FDA Approves Abbott’s Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries

April 2, 1:00 PM

FDA approves Abbott Laboratories' TriClip TEER system for treating tricuspid regurgitation. Clip technology offers non-invasive repair, fast recovery, and significant improvement in quality of life. Already approved in 50+ countries

ABT

2 minute read

Vivek Ramaswamy-Founded Roivant’s Anti-Inflammatory Drug Aces Mid-Stage Study

By Vandana Singh

April 2, 12:31 PM

Roivant Sciences and Priovant Therapeutics report Phase 2 results for brepocitinib in treating non-anterior non-infectious uveitis. Week 24 data show promising efficacy, with lower treatment failure rates and positive secondary endpoints. Roivant authorizes a $1.5 billion share repurchase program

ROIV

2 minute read

Gene Therapy Side Effects: Verve Therapeutics Halts Enrollment Of Lead Gene Therapy Trial In Patients With Bad Cholesterol

By Vandana Singh

April 2, 12:19 PM

Verve Therapeutics' latest update on the Heart-1 Phase 1b trial of VERVE-101. Explore VERVE-102's development and regulatory clearances for the Heart-2 clinical trial, offering hope for patients with cardiovascular conditions.

BEAM

2 minute read

Eli Lilly Stock Navigates Weight-Loss Drug Competition With Technical Resilience

By Surbhi Jain

April 2, 11:39 AM

Eli Lilly's stock has performed well over the past year, gaining 116.84%. So far in 2024, the stock has returned 29.45% to investors.

LLY

4 minute read

Abbott Receives FDA Approval For TriClip, First-Of-Its-Kind Device To Repair Leaky Tricuspid Heart Valve

By Benzinga Newsdesk

April 2, 9:01 AM

TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgeryMore than 1.6 million people in the U.S. are affected by

ABT

2 minute read

Telomir Pharmaceuticals’ To Present Pre-Clinical Data For Age-Reversal Drug Telomir-1 At The National Press Club In Washington, DC, On April 15, 2024

By Benzinga Newsdesk

April 2, 8:39 AM

Telomir's pre-clinical studies demonstrate its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomeraseNew York Times article supports

TELO

2 minute read

Mirum Pharmaceuticals’ LIVMARLI Receives Reimbursement Recommendation By Canada’s CADTH For Patients With Cholestatic Pruritus In Alagille Syndrome

By Benzinga Newsdesk

April 2, 8:37 AM

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder- LIVMARLI is the first and only approved medication to

MIRM

2 minute read

Corbus Announces Dosing Of First Patient In U.S. Phase 1 Clinical Trial Of Its Next Generation Nectin-4 Targeting ADC

By Benzinga Newsdesk

April 2, 8:28 AM

Study enrolling patients with metastatic urothelial cancer (mUC) and other Nectin-4 enriched tumors Emerging clinical profile from CSPC's Phase 1 China study indicates differentiation from PADCEVNORWOOD, Mass.,

CRBP

2 minute read

EXCLUSIVE: PainReform Reaches 50% Enrollment Target For Phase 3 Study For Its Lead Postoperative Pain Drug

By Vandana Singh

April 2, 8:00 AM

PainReform hits a 50% enrollment target in the Phase 3 trial for PRF-110 in bunionectomy. No serious adverse events were reported. Over 200 patients enrolled across 8 U.S. sites. CEO Ilan Hadar is optimistic about PRF-110's potential to revolutionize postoperative pain management.

PRFX